Cargando…

Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens

The recent approval of experimental phage therapies by the FDA and other regulatory bodies with expanded access in cases in the United States and other nations caught the attention of the media and the general public, generating enthusiasm for phage therapy. It started to alter the situation so that...

Descripción completa

Detalles Bibliográficos
Autores principales: Karn, Subhash Lal, Gangwar, Mayank, Kumar, Rajesh, Bhartiya, Satyanam Kumar, Nath, Gopal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620811/
https://www.ncbi.nlm.nih.gov/pubmed/37928478
http://dx.doi.org/10.3389/fmed.2023.1209782
_version_ 1785130282005823488
author Karn, Subhash Lal
Gangwar, Mayank
Kumar, Rajesh
Bhartiya, Satyanam Kumar
Nath, Gopal
author_facet Karn, Subhash Lal
Gangwar, Mayank
Kumar, Rajesh
Bhartiya, Satyanam Kumar
Nath, Gopal
author_sort Karn, Subhash Lal
collection PubMed
description The recent approval of experimental phage therapies by the FDA and other regulatory bodies with expanded access in cases in the United States and other nations caught the attention of the media and the general public, generating enthusiasm for phage therapy. It started to alter the situation so that more medical professionals are willing to use phage therapies with conventional antibiotics. However, more study is required to fully comprehend phage therapy’s potential advantages and restrictions, which is still a relatively new field in medicine. It shows promise, nevertheless, as a secure and prosperous substitute for antibiotics when treating bacterial illnesses in animals and humans. Because of their uniqueness, phage disinfection is excellent for ready-to-eat (RTE) foods like milk, vegetables, and meat products. The traditional farm-to-fork method can be used throughout the food chain to employ bacteriophages to prevent food infections at all production stages. Phage therapy improves clinical outcomes in animal models and lowers bacterial burdens in numerous preclinical investigations. The potential of phage resistance and the need to make sure that enough phages are delivered to the infection site are obstacles to employing phages in vivo. However, according to preclinical studies, phages appear to be a promising alternative to antibiotics for treating bacterial infections in vivo. Phage therapy used with compassion (a profound understanding of and empathy for another’s suffering) has recently grown with many case reports of supposedly treated patients and clinical trials. This review summarizes the knowledge on the uses of phages in various fields, such as the food industry, preclinical research, and clinical settings. It also includes a list of FDA-approved bacteriophage-based products, commercial phage products, and a global list of companies that use phages for therapeutic purposes.
format Online
Article
Text
id pubmed-10620811
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106208112023-11-03 Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens Karn, Subhash Lal Gangwar, Mayank Kumar, Rajesh Bhartiya, Satyanam Kumar Nath, Gopal Front Med (Lausanne) Medicine The recent approval of experimental phage therapies by the FDA and other regulatory bodies with expanded access in cases in the United States and other nations caught the attention of the media and the general public, generating enthusiasm for phage therapy. It started to alter the situation so that more medical professionals are willing to use phage therapies with conventional antibiotics. However, more study is required to fully comprehend phage therapy’s potential advantages and restrictions, which is still a relatively new field in medicine. It shows promise, nevertheless, as a secure and prosperous substitute for antibiotics when treating bacterial illnesses in animals and humans. Because of their uniqueness, phage disinfection is excellent for ready-to-eat (RTE) foods like milk, vegetables, and meat products. The traditional farm-to-fork method can be used throughout the food chain to employ bacteriophages to prevent food infections at all production stages. Phage therapy improves clinical outcomes in animal models and lowers bacterial burdens in numerous preclinical investigations. The potential of phage resistance and the need to make sure that enough phages are delivered to the infection site are obstacles to employing phages in vivo. However, according to preclinical studies, phages appear to be a promising alternative to antibiotics for treating bacterial infections in vivo. Phage therapy used with compassion (a profound understanding of and empathy for another’s suffering) has recently grown with many case reports of supposedly treated patients and clinical trials. This review summarizes the knowledge on the uses of phages in various fields, such as the food industry, preclinical research, and clinical settings. It also includes a list of FDA-approved bacteriophage-based products, commercial phage products, and a global list of companies that use phages for therapeutic purposes. Frontiers Media S.A. 2023-10-19 /pmc/articles/PMC10620811/ /pubmed/37928478 http://dx.doi.org/10.3389/fmed.2023.1209782 Text en Copyright © 2023 Karn, Gangwar, Kumar, Bhartiya and Nath. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Karn, Subhash Lal
Gangwar, Mayank
Kumar, Rajesh
Bhartiya, Satyanam Kumar
Nath, Gopal
Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
title Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
title_full Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
title_fullStr Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
title_full_unstemmed Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
title_short Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
title_sort phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620811/
https://www.ncbi.nlm.nih.gov/pubmed/37928478
http://dx.doi.org/10.3389/fmed.2023.1209782
work_keys_str_mv AT karnsubhashlal phagetherapyarevolutionaryshiftinthemanagementofbacterialinfectionspioneeringnewhorizonsinclinicalpracticeandreimaginingthearsenalagainstmicrobialpathogens
AT gangwarmayank phagetherapyarevolutionaryshiftinthemanagementofbacterialinfectionspioneeringnewhorizonsinclinicalpracticeandreimaginingthearsenalagainstmicrobialpathogens
AT kumarrajesh phagetherapyarevolutionaryshiftinthemanagementofbacterialinfectionspioneeringnewhorizonsinclinicalpracticeandreimaginingthearsenalagainstmicrobialpathogens
AT bhartiyasatyanamkumar phagetherapyarevolutionaryshiftinthemanagementofbacterialinfectionspioneeringnewhorizonsinclinicalpracticeandreimaginingthearsenalagainstmicrobialpathogens
AT nathgopal phagetherapyarevolutionaryshiftinthemanagementofbacterialinfectionspioneeringnewhorizonsinclinicalpracticeandreimaginingthearsenalagainstmicrobialpathogens